Daniel A. Weiser
<p><span style="text-decoration: underline;"><strong>Childhood cancer research laboratory</strong></span></p>
<p>Our laboratory is focused on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. In such patients with typically incurable cancer, we are striving to identify new approaches to and types of treatment. We have multiple ongoing projects:</p>
<p><strong>+ Identification of biologic drivers of ultra-high-risk neuroblastoma</strong>. Neuroblastoma is one of the most common and deadly childhood cancers. Despite intensive research, there are limited therapeutic strategies for patients with <em>de novo </em>chemotherapy resistance that leads to particularly poor outcomes. We have been studying neuroblastoma since 2009 and are identifying additional biologic drivers of highly lethal tumors.</p>
<p>We compare tumor features from patients with early death from tumor progression compared to those with a maintained complete response. We assess unique histo-morphologic and proteomic features and computationally integrate these data with genomic and transcriptomic datasets to develop a combined predictor of primary refractory disease. Patients with this entity require non-standard and/or intensified treatment. Oncogenic drivers are being characterized in the lab which will facilitate strategies for novel pharmacologic intervention.</p>
<p><strong>+ Characterization of neuroblastoma development from neural crest cells</strong>. We are studying pathways and interactions that results in uncontrolled cell proliferation early in neuroblastoma development with an ultimate goal of identifying new targets and approaches for pharmacologic intervention.</p>
<p><strong>+ Evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma</strong>. With expected outcomes lagging behind those of more common childhood cancers, children with neuroblastoma require new approaches to treatment. Our lab works with multiple international clinical and research consortium groups to perform preclinical studies that substantiate human clinical trials. </p>
<p><strong>+ Detection of circulating tumor DNA in osteosarcoma</strong>. With no reliable non-invasive approach for disease monitoring during and after treatment, we are applying cutting edge next-generation sequencing approaches to identify solid tumors with a blood-based “liquid” biopsies. This will allow clinicians to assess tumor responsiveness to chemotherapy and predict likelihood of recurrence.</p>
<p><strong>+ Assessment of accelerated aging using miRNA-seq in survivors of childhood cancer</strong>. Chemotherapy has many untoward effects on healthy cells and leads to many signs of accelerated aging in children treated for cancer. Using a known microRNA “aging” signature discovered at Albert Einstein College of Medicine, we are studying what causes this phenotype in childhood cancer, with a goal of offering improved intervention to minimize long-term toxicity of treatment.</p>
<p><strong><span style="text-decoration: underline;">Physician Summary</span></strong></p>
<p>Daniel A. Weiser, MD, is board-certified in pediatric hematology/oncology with clinical expertise in neuroblastoma and other tumors of the adrenal glands, kidneys, liver, and gonads. He is the medical director of the intra-abdominal solid tumor program at the Children’s Hospital at Montefiore and brings together a highly specialized multi-disciplinary care team to provide comprehensive treatment for diverse pediatric malignancies. In addition, Dr. Weiser directs a childhood cancer research laboratory that focuses on the identification of new targeted agents for cancer therapy, especially in the treatment of rare and aggressive malignancies such as neuroblastoma. His research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise for improving management of all patients with solid tumors.</p>
<p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), Advances in Neuroblastoma Research Association (ANRA), National Pediatric Cancer Foundation (NPCF), and the American Academy of Pediatrics (AAP). He has received numerous awards including the Brigid Leventhal Special Merit Award from ASCO and the Conquer Cancer Foundation, and a prestigious K12 from the National Cancer Institute for the training of the next generation of physician-scientists in pediatric cancer. Dr. Weiser is actively involved in teaching and mentorship of trainees, and takes great pride in providing advanced and compassionate care to his patients and their families.</p>
<p><strong>Clinical Expertise</strong></p>
<ul>
<li>Neuroblastoma (adrenal tumors)</li>
<li>Wilms tumor (renal tumors)</li>
<li>Hepatoblastoma (liver tumors)</li>
<li>Germ cell tumors (including testicular and ovarian tumors)</li>
<li>Thyroid and other rare tumors</li>
<li>Experimental therapeutics</li>
<li>Cancer genetics and biomarkers</li>
</ul>
<p><strong>Board Certifications</strong></p>
<ul>
<li>Pediatrics</li>
<li>Pediatric Hematology/Oncology</li>
</ul>
<p><strong>Professional Education</strong></p>
<ul>
<li>M.D. – Stony Brook University, NY</li>
<li>Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Chief Residency – Children’s Hospital of NY-Presbyterian, Columbia University, NY</li>
<li>Fellowship – The Children’s Hospital of Philadelphia, PA</li>
</ul>
DR. Weiser's clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma, and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers.
Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others.
<p>Daniel A. Weiser, MD, is a Medical Director of the Intra-abdominal Solid Tumor Program in the Pediatrics Hematology/Oncology department at Children’s Hospital at Montefiore. He is also Associate Professor in the Pediatrics and Genetics departments at the Albert Einstein College of Medicine. His clinical focuses are neuroblastoma and adrenal tumors, Wilms tumor and other kidney (renal) tumors, hepatoblastoma and other liver tumors, germ cell tumors (including testicular and ovarian tumors), Thyroid and other rare tumors, experimental therapeutics, and cancer genetics and biomarkers. Dr. Weiser is actively involved in teaching and mentorship of trainees and takes great pride in his active participation in patient care.</p><p>Dr. Weiser received his Bachelor of Science in Neurobiology in 1995 at Haverford College, PA. In 2004, he received his Doctor of Medicine at Stony Brook University School of Medicine, NY. He is currently earning his Master of Science in Translational Research at the University of Pennsylvania. He began a residency in Pediatrics at the New York-Presbyterian, Columbia University in 2007. Dr. Weiser then completed a three-year fellowship in Pediatric Hematology/Oncology at The Children’s Hospital of Philadelphia. </p><p>Dr. Weiser’s research goals are to understand the role of certain genes in the risk, development, and treatment of cancer. The approaches taken and agents studied hold promise in the treatment of all solid tumors. Dr. Weiser’s laboratory focuses on childhood cancer research with a goal of elucidating the underlying biology of the most aggressive malignancies. He has multiple ongoing projects, such as identification of biologic drivers of neuroblastoma at ultra-high risk for treatment failure, characterization of neuroblastoma development from neural crest cells, and evaluation of novel combinatorial targeted therapeutic approaches in neuroblastoma, among others. His research has been published in many reviewed journals. </p><p>Dr. Weiser participates in the efforts of a number of professional organizations including the Children’s Oncology Group (COG), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), and the American Academy of Pediatrics (AAP). He has received many awards including the Brigid Leventhal Special Merit Award through ASCO, and he has been awarded a prestigious K12 from the NCI for the training of the next generation of physician-scientists in pediatric cancer.</p><p>He is board certified in Pediatric Hematology/Oncology and General Pediatrics.</p>
Asli S. Sucu
Shawn K. Samuel
Marjan Rahmanian
<p><span>Dr. Marjan Rahmanian is an Assistant Professor of Medicine and Neurology. She is an Associate Medical Director of Cardiothoracic Intensive Care Unit at Montefiore Medical Center. She is also Medical Director of Physician Assistant Critical Care Residency program. She completed her Internal Medicine residency at Hackensack Meridian Mountainside Medical Center, followed by a fellowship in Critical Care Medicine at Mount Sinai Medical Center. After completing her training, she joined the faculty of the Albert Einstein College of Medicine in New York, where she served as an Associate Director of Cardiothoracic Surgical ICU at Montefiore Medical center. As a cardiac intensivist, Dr. Rahmanian focuses on the management of post heart surgery like CABG, valve replacemant, Mechanical Circulatory Support like,ECMO, LVAD,Impella, heart and lung transplant.</p>
<ol>
<li>Maintaining Hemodynamic and Metabolic Homeostasis in Anheptaic Critically Ill Patients. Khan R, Go R, Kapoor S, Dharshan A, <strong>Marjan</strong> <strong>Rahmanian </strong>, Manasia A, Bassily-Marcus A, Kohli-Seth R, Oropello J, Benjamin E. CHEST. October 2012;142:390A-390A</li>
<li>The Heart Point Sign: An Ultrasonographic Confirmation Of Pneumothorax. R. Khan, M. <strong>Marjan</strong> <strong>Rahmanian</strong>, M. Kaufman, A. Bassily Marcus, J. Oropello. ajrccm-conference.2013.187.1 MeetingAbstracts.A1539</li>
<li>Cardiothoracic Surgical ICU Boot Camp can improve cardiovascular critical care knowledge among trainees. <strong>Marjan Rahmanian, </strong>MD; Lewis Eisen, MD; Adam Keene, MD; Rosemarie Conigliaro, MD; Anthony Carlese, DO ATS2018 Poster Presentation </li>
<li>Midodrine: Breaking New Ground in The Treament of Chylothorax: Dolly Patel, DO; <strong>Marjan Rahmanian, </strong>MD; Javed Iqbal, MD; Scott Scheinin, MD; Joshoua Lee, MD; Harish Seethamraju, MD Chest 2019 Poster Presentation</li>
<li>Lactate Dehydrogenase is Associated with Hemorrhagic Stroke During Extracorporeal Membrane Oxygenation for COVID-19 <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Saeed, O.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Uehara, M.</a>; <strong>Marjan</strong> <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank"><strong>Rahmanian</strong>.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Chen, J. T.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Carlese, A.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Mohamed, A.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Ashley, J.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Mellas, N.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Forest, S.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Goldstein, D.</a>; <a href="https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-201…; target="_blank">Jorde, U.</a>.<em>ASAIO Journal ; 68(Supplement 3):19, 2022.</em></li>
<li><a href="https://einstein.pure.elsevier.com/en/publications/hiv-dr-heartkidney-t…; target="_blank">HIV D+/R+ heart/kidney transplantation: First case report</a> <a href="https://einstein.pure.elsevier.com/en/persons/vagish-s-hemmige" target="_blank">Hemmige, V.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/omar-saeed" target="_blank">Saeed, O.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/yoram-a-puius" target="_blank">Puius, Y. A.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/yorg-al-azzi" target="_blank">Azzi, Y.</a>, Colovai, A., Borgi, J., <a href="https://einstein.pure.elsevier.com/en/persons/daniel-j-goldstein" target="_blank">Goldstein, D. J.</a>, Marjan Rahmanian, <a href="https://einstein.pure.elsevier.com/en/persons/anthony-j-carlese" target="_blank">Carlese, A.</a>, <a href="https://einstein.pure.elsevier.com/en/persons/ulrich-p-jorde" target="_blank">Jorde, U. P.</a> & <a href="https://einstein.pure.elsevier.com/en/persons/snehal-r-patel" target="_blank">Patel, S. R.</a>, Mar 2023, In: <a href="https://einstein.pure.elsevier.com/en/persons/anthony-j-carlese" target="_blank">Journal of Heart and Lung Transplantation.</a> 42, 3, p. 406-408 3 p. </li>
<li>Chest Tube Insertion, Needle Thoracostomy, And Pericardiocentesis During In-hospital Cardiac Arrest <a title="Luke Andrea" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Luke Andrea</a>, Marjan Rahmanian, <a title="Anthony Carlese" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Anthony Carlese</a>, <a title="Ariel Shiloh" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Ariel Shiloh</a>, <a title="Rithvik Balakrishnan" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Rithvik Balakrishnan</a>, <a title="Aron Soleiman" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Aron Soleiman</a>, <a title="Michelle Gong" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Michelle Gong</a> and <a title="Ari Moskowitz" href="https://www.ahajournals.org/doi/10.1161/circ.146.suppl_1.247" target="_blank">Ari Moskowitz</a> Circulation. 2022;146:A247</li>
</ol>
Kerry A. Morrone
<p>Anemia, hospitalist medicine, general pediatrics</p>
Dr. Morrone focuses on classical hematology, particularly sickle cell disease and hemoglobinopathies, platelet disorders, thrombosis, and bone marrow failure syndromes.
Dr. Morrone is committed to improving quality of care and health care utilization in chronic illness, particularly sickle cell disease, and thalassemia through her research
<p>Kerry Morrone, MD, is an Assistant Professor of Pediatrics at the Albert Einstein College of Medicine, the Director of the Sickle Cell Program and the Director of the Pediatric Hematology Oncology Fellowship Program at Montefiore. Dr. Morrone focuses on classical hematology, particularly sickle cell disease and hemoglobinopathies, platelet disorders, thrombosis, and bone marrow failure syndromes.</p><p>Dr. Morrone graduated from New York University, earning her Bachelor of Arts in Biology in 2003. She then attended the Albert Einstein College of Medicine, where she received her Doctor of Medicine in 2007 and was inducted into the Alpha Omega Alpha Honor Medical Society. Dr. Morrone completed her pediatric residency, chief residency, and pediatric hematology oncology fellowship all at the Albert Einstein College of Medicine. She has also been recognized for her teaching efforts many times and won the Leo M. Davidoff Society – Albert Einstein College of Medicine Teaching Award in 2010 and 2015.</p><p>Dr. Morrone is committed to improving quality of care and health care utilization in chronic illness, particularly sickle cell disease, and thalassemia through her research. Other current research interests include pulmonary complications of sickle cell disease particularly asthma and acute chest syndrome, in addition to infectious complications and thrombotic complications of sickle cell disease.</p>
Giliane Joseph
Nomeda Balcetis
Gabriella C. Azzarone
<p>Pediatric Hospital Medicine</p>
<p>Medical Student & Resident Education</p>
<p>In-Patient Asthma Management</p>
<p>Gabriella C. Azzarone, MD, FAAP, is an attending physician at the Children’s Hospital at Montefiore Einstein and Associate Professor, Pediatrics at our Albert Einstein College of Medicine. She is also Co-Director, Pediatrics Clerkship and Course Director, Pediatrics Acting Internship at Einstein. Dr. Azzarone’s clinical focus is in pediatric care, ensuring safe and quality care for hospitalized children.</p><p>In 1996, Dr. Azzarone received her Bachelor of Arts from Barnard College, Columbia University, then completed her postbaccalaureate premedical studies at the same institution in 1998. In 2003, she earned her Doctor of Medicine from New York University School of Medicine. For her postgraduate training, Dr. Azzarone came to Einstein, completing her internship and residency in pediatrics in 2007, taking on the role of Chief Resident in her final year. In 2015, Dr. Azzarone completed a clinical quality fellowship program with the Greater New York Hospital Association and United Hospital Fund.</p><p>Dr. Azzarone’s research focus is on the inpatient management of pediatric respiratory illnesses and firearm-related violence prevention through education, advocacy, research and clinical care. She has shared her work through peer-reviewed journals, book chapters, review articles, abstracts, workshops and invited presentations. She is also an ad hoc reviewer for <em>Pediatrics</em> and <em>Hospital Pediatrics</em>.</p><p>Dr. Azzarone is a Diplomate of the American Board of Pediatrics. She is a Fellow of the American Academy of Pediatrics and a member of the American Medical Association. In 2017, Dr. Azzarone was inducted into the Leo M. Davidoff Society.</p>